Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

Table 2 Summary of quality indicators for studies assessing aspirin in patients with diabetes for the primary prevention of major adverse cardiovascular events

Study, Year	Allocation Concealment	Blinding of participants and outcome-assessors	Placebo - controlled	Intention to Treat Analysis	Lost to Follow up Accounted	Potential Baseline Difference	JADAD Score (Range 0-5)
PHS, 1989#	Yes	Yes	Yes	Undetermined	Yes	No	5
ETDRS, 1992	Yes	Yes	Yes	Yes	Yes	No	4
HOT, 1998	Yes	Yes	Yes	Undetermined	Yes	No	4
PPP, 2003#	Yes	No	No*	Yes	Undetermined	No	3
WHS, 2005#	Undetermined	Yes	Yes	Yes	Yes	No	4
POPADAD, 2008	Yes	Yes	Yes**	Undetermined	Yes	No	5
JPAD, 2008	No	No	No	Yes	Yes	No	3

PHS: Physicians' Health Study, ETDRS: Early Treatment Diabetic Retinopathy Study, HOT: Hypertension Optimal Treatment, PPP: Primary Prevention Project, WHS: Women's' Health Study, POPADAD: Prevention and Progression of Arterial Disease and Diabetes Trial, JPAD: Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes, # methods papers reviewed, * and/or comparator of vitamin E 300 mg once daily, **and/or comparator of anti-oxidant tablet

ISSN: 1475-2840